A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2012
At a glance
- Drugs AGS 009 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 07 Jun 2012 Results have been presented at EULAR-2012 according to an Argos Therapeutics media release.
- 27 Jan 2012 Actual end date (Dec 2011 ) added as reported by ClinicalTrials.gov.